Pipeline

R&D na Sorrento yana mai da hankali kan haɓaka sabbin abubuwa a cikin COVID-19, maganin cutar kansa, cikakken kula da ciwo da cututtukan autoimmune.

Mabuɗin Shirye-shirye Bayyanawa Preclinical Hakan na I Phase II Mataki na III/Pivotal FDA Approval
Shirye-shiryen COVID-19  

COVISTIX (diagnostic) Gwajin Antigen gaggawa

*

Izinin Amfani da Gaggawa (EUA) a Mexico (COFEPRIS), Brazil (ANVISA), da CE Alama a Turai

COVIMARK™ (diagnostic) Gwajin Antigen gaggawa

*

Aikace-aikacen da aka ƙaddamar a cikin Amurka da Kanada don Izinin Amfani da Gaggawa (EUA)

VIREX (diagnostic) A Home Diagnostic

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (maganin magani) Neutralizing Antibody (IV) a cikin marasa lafiya da marasa lafiya

20%*

FUJOVEE (Abivertinib) Mummunan COVID-19 a cikin Marasa lafiya na ICU

82%*

Muhimmin Gwajin da ke jiran Cirewar FDA

OQORY™ (COVI-MSC) ARDS saboda COVID-19 a cikin marasa lafiya na ICU

82%*

Muhimmin gwaji a Brazil

Mpro Mai hanawa (kwayoyin baka) Anti rigakafi

40%*

Omicron mRNA rigakafin maganin

20%*

Mabuɗin Shirye-shirye Bayyanawa Preclinical Hakan na I Phase II Mataki na III/Pivotal FDA Approval
immunotherapy  

FUJOVEE (Abivertinib) Bayanin NSCLC

82%*

FUJOVEE (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE (Abivertinib) prostate

20%*

FUJOVEE (Abivertinib) Lupus

20%*

FUJOVEE (Abivertinib) MS

20%*

FUJOVEE (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*A cikin haɗin gwiwa tare da Lee's Pharm a China

PD-L1 (STI-3031)** Cercical Cancer

82%*

** A Amurka kuma tare da haɗin gwiwar ImmuneOncia a Koriya

CD47 Tumburai masu ƙarfi

40%*

CD38 DAR-T Multiye Myeloma

40%*

Saukewa: CD38D Amyloidosis, Multiple Myeloma, T-ALL, da esophageal

40%*

Seprehvec™ oncolytic cutar Ciwon Ciwon Ciki; Ciwon daji na CNS

40%*

Farashin BCMA Tuwon Ruwa

20%*

Bevacizumab-ADNAB™ Ciwon daji na Endometrial

40%*

A haɗin gwiwa tare da Mayo Clinic

Bevacizumab-ADNAB™ Ovarian Ciwon daji

40%*

A haɗin gwiwa tare da Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

A haɗin gwiwa tare da Mayo Clinic

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Mabuɗin Shirye-shirye Bayyanawa Preclinical Hakan na I Phase II Mataki na III/Pivotal FDA Approval
Pain  

ZTlido® 1.8%
Neuralgia Postherpetic - PHN

99.8%*

Gloperba®
Maganin Gout (Na baka)

99.8%*

SEMEXA (SP-102) Lumbar Radicular / Sciatica Pain

82%*

SP-103 (Tsarin Topical Lidocaine 5.4%) Ciwon Baya

60.2%*

SP-104 (An jinkirta fashe Low Dose Naltrexone) Fibromyalgia

20%*

RTX (resiferatoxin)
Epidural allura
Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Kankara

60.3%*

Sunan marayu

RTX (resiferatoxin)
Hanyar intra-articular
Matsakaici zuwa Ƙunƙarar Ƙifin OA

60.2%*

Mabuɗin Shirye-shirye Bayyanawa Preclinical Hakan na I Phase II Mataki na III/Pivotal FDA Approval
Isar da Magungunan Lymphatic  

Sofusa® anti-TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

A haɗin gwiwa tare da Mayo Clinic
Shirye-shiryen COVID-19
Mabuɗin Shirye-shirye (Alamar) Phase
COVISTIX (diagnostic) FDA EU
COVIMARK™ (diagnostic) FDA EU
VIREX (diagnostic) PH III
COVISHIELD™ (maganin magani) PH I
FUJOVEE (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (kwayoyin baka) Ph II
Omicron mRNA rigakafin Preclinical
immunotherapy
Mabuɗin Shirye-shirye (Alamar) Phase
FUJOVEE (Abivertinib) Ph III
FUJOVEE (Abivertinib) Ph II
FUJOVEE (Abivertinib) Preclinical
FUJOVEE (Abivertinib) Preclinical
FUJOVEE (Abivertinib) Preclinical
FUJOVEE (Abivertinib) Preclinical
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Tsarin Tumor) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
Saukewa: CD38D (Amyloidosis, Multiple Myeloma, T-ALL, da esophageal) Ph I
Seprehvec™ oncolytic cutar (Tsarin Ciwon Ciwon Ciki; Ciwon Ciwon Ciki) PH I
Farashin BCMA (Magungunan Liquid) Preclinical
Bevacizumab-ADNAB™ (Cancer Endometrial) Ph I
Bevacizumab-ADNAB™ (Cancer Ovarian) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Pain
Mabuɗin Shirye-shirye (Alamar) Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
Gloperba® 1.8% Maganin Gout (Na baka) FDA Approval
SEMEXA (SP-102) Ph III
SP-103 (Tsarin Topical Lidocaine 5.4%) Ph II
SP-104 (An jinkirta fashe Low Dose Naltrexone) Preclinical
RTX (resiferatoxin) Epidural allura Ph II
RTX (resiferatoxin) Hanyar intra-articular Ph II
Bayarwa Lymphatic
Mabuɗin Shirye-shirye (Alamar) Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I